

Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation

Weili Zhan
Yanhong Kang
Ning Chen
Chongshan Mao
Yi Kang
Jia Shang

Department of Infectious Diseases,
Henan Provincial People's Hospital,
Zhengzhou, Henan, China

Abstract: The hepatitis B virus (HBV) has caused acute and chronic liver diseases in ~350 million infected people worldwide. Halofuginone (HF) is a plant alkaloid which has been demonstrated to play a crucial role in immune regulation. Our present study explored the function of HF in the immune response of HBV-infected Sprague Dawley (SD) rats. Plasmid containing pCDNA3.1-HBV1.3 was injected in SD rats for the construction of an acute HBV-infected animal model. Our data showed that HF reduced the high concentrations of serum hepatitis B e-antigen, hepatitis B surface antigen, and HBV DNA induced by HBV infection. HF also reduced the number of T helper (Th)17 cells and the expression of interleukin (IL)-17 compared with the pCDNA3.1-HBV1.3 group. Moreover, pro-inflammatory cytokine levels (IL-17, IL-23, interferon- γ , and IL-2) were downregulated and anti-inflammatory cytokine levels (IL-4 and IL-13) were upregulated by HF. Through further research we found that the expression of AMP-activated protein kinase (AMPK) and IKBA which suppressed NF- κ B activation was increased while the expression of p-NF- κ B P65 was decreased in pCDNA3.1-HBV1.3+HF group compared with pCDNA3.1-HBV1.3 group, indicating that HF may work through the activation of AMPK. Finally, our conjecture was further verified by using the AMPK inhibitor compound C, which counteracted the anti-inflammation effect of HF, resulting in the decreased expression of AMPK, IKBA and increased expression of p-NF- κ B P65 and reduced number of Th17 cells. In our present study, HF was considered as an anti-inflammatory factor in acute HBV-infected SD rats and worked through AMPK-mediated NF- κ B p65 inactivation. This study implicated HF as a potential therapeutic strategy for hepatitis B.

Keywords: halofuginone, hepatitis B virus, inflammation, AMPK

Abbreviations

HBV, hepatitis virus B; HF, halofuginone; CC, compound C; qRT-PCR, quantitative real-time polymerase chain reaction; Th, T helper.

Introduction

The hepatitis B virus (HBV) is a kind of hepatotropic DNA virus which has caused acute and chronic liver diseases in ~350 million infected people worldwide.¹ HBV is transmitted by mother-to-child transmission, sex transmission, and blood transmission. It causes one of the most common infectious diseases (hepatitis B) in the world through a high level of viral replication. Researches have indicated that HBV plays a vital role in many liver diseases including cirrhosis and hepatocellular carcinoma.² The pathogenic mechanism of HBV is thought to be related to immune response instead of directly causing cytopathy of hepatocytes.^{3,4} HBV is able to trigger immune

Correspondence: Jia Shang
Department of Infectious Diseases,
Henan Provincial People's Hospital, No 7
Weiwu Road, Jinshui District, Zhengzhou,
Henan 450000, China
Tel +86 371 6558 0014
Email shangjiahn@163.com

response in the presence of HBV-specific antigens which cause T-cell response.⁵ However, the relationship between HBV infection and immune response still remains unclear. Hence, a better understanding of the pathogenic mechanisms of HBV infection and more effective therapeutic strategies for hepatitis B are required.

Halofuginone (HF), a natural low-molecular-weight plant alkaloid, isolated from the plant *Dichroa febrifuga*, has been reported to have antimalarial activity.⁶ Researches revealed that HF worked as an anti-fibrotic agent.^{7,8} Studies also showed that HF had antitumor effect by inhibiting cancer cell proliferation, metastasis, and invasion in many kinds of tumors such as hepatocellular carcinoma, breast cancer, and melanoma.^{9–11} HF is also reported to be involved in several signal pathways such as PI3K/AKT, Stat3, NF- κ B, and MAPK pathways.^{12–14} Evidence also supported the potential role of HF in immune regulation. A study by Park et al discovered that HF regulated the balance between T helper (Th)17 and Treg cells to ameliorate autoimmune arthritis in mice.¹⁵ HF also acted as an attractive immunomodulator and anti-inflammatory agent to suppress activated peripheral blood T-cell functions through inhibiting NF- κ B and p38 MAPK signaling pathway.¹⁶ However, whether HF can ameliorate the inflammation induced by HBV infection still remains unknown and needs further research.

In this study, we aimed to elucidate the function of HF on inflammation in acute HBV-infected Sprague Dawley (SD) rats. We found that HF suppressed inflammation by decreasing the number of Th17 cells and pro-inflammatory cytokine levels via AMP-activated protein kinase (AMPK)-mediated NF- κ B p65 inactivation. Taken together, our results suggest that HF provides a novel insight into the mechanism and treatment of hepatitis B.

Materials and methods

Construction of animal model and grouping

Female, 6–9 weeks old SD rats were purchased from the Laboratory Animal Center of Henan Provincial People's Hospital. All the animals were fed under specific pathogen-free conditions. Animal experiments and welfare were performed according to the guidelines of the National Institute of Health. The study was approved by the Medical Ethics Committee of Henan Provincial People's Hospital. SD rats were transfected with pCDNA3.1-HBV1.3 plasmid which contained a 1.3-length transgene HBV or just pCDNA3.1 as control, respectively (constructed in the laboratory). Twenty micrograms of plasmids in phosphate-buffered saline (PBS; Double-Helix Biotech, London, UK) were injected

into the tail vein of each rat for the acute HBV-infected animal model.¹⁷

The animals were divided into 4 groups with 5 rats in each group as follows: pCDNA3.1 group, SD rats were transfected with pCDNA3.1 plasmid; pCDNA3.1-HBV1.3 group, SD rats were transfected with pCDNA3.1-HBV1.3 plasmid; pCDNA3.1-HBV1.3+HF group, pCDNA3.1-HBV1.3 plasmid transfected rats were treated with HF (1 mg/kg) by injection every other day; pCDNA3.1-HBV1.3+HF+compound C (CC) group, pCDNA3.1-HBV1.3 plasmid transfected rats were co-treated with CC (3 μ M) and HF (1 mg/kg) by injection every other day. The peripheral blood of each rat in the different groups was collected and measured at 1, 4, 7, and 10 days post-transfection. After 10 days post-transfection, rats were sacrificed and livers were harvested for further analyses.

Quantification of hepatitis B e-antigen (HBeAg), hepatitis B surface antigen (HBsAg), and HBV DNA

Serum HBeAg, HBsAg, and HBV DNA levels were measured in the laboratory according to a method described previously.¹⁸ Serum HBeAg was measured using the Abbott Diagnostics HBeAg kit (Abbott Diagnostics, Abbott Park, IL, USA), and HBsAg was measured on ARCHITECT platform (Abbott Laboratories, Abbott Park, IL, USA) by enzyme immunoassay according to the manufacturer's instructions. The quantification of HBV DNA was tested using the Abbott RealTime HBV test (Abbott Molecular, Des Plaines, IL) according to the manufacturer's instructions.

Flow cytometry

Peripheral blood samples from rats were lysed by NH_4Cl lysis solution to remove red blood cells and washed twice with PBS. For the staining of intracellular cytokine, CaltagTM, Fix & Perm[®] reagents (Thermo Fisher Scientific, Waltham, MA, USA) were used following the manufacturer's instructions. Then, samples containing lymphomononuclear cells were incubated with fluorochrome-labeled antibodies at 5×10^5 cells for 30 minutes at 4°C and were analyzed on a flow cytometer (FACStar; BD Biosciences, San Jose, CA, USA). The following antibodies were used in this study: fluorescein isothiocyanate-conjugated anti-CD4 (BD Biosciences) and phycoerythrin-conjugated anti-interleukin (IL)-17 (BD Biosciences).

Western blot

Proteins were extracted from livers using RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) after grinding by liquid nitrogen. Lysates were centrifuged at 12,000 rpm for 15 minutes at 4°C, and the protein

concentrations of supernatants were measured using the Bio-Rad protein assay kit (Beijing Solarbio Science & Technology Co, Ltd, Beijing, China) according to the manufacturer's instructions. After incubation with 6× sample buffer (Sigma-Aldrich Co, St Louis, MO, USA) at 100°C for 5 minutes, the proteins were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and then transferred onto polyvinylidene difluoride membranes. After incubation with blocking buffer (5% nonfat milk in Tris-buffered saline) for 60 minutes at room temperature, the membranes were incubated with the following primary antibodies obtained from Abcam (Cambridge, UK), respectively: anti-IL-17 antibody, anti-AMPK antibody, anti-p-NF-κB P65 antibody, anti-IKBA antibody, and anti-GAPDH antibody at 4°C overnight. The membranes were then incubated with the corresponding secondary antibodies (1:2,000; Cell Signaling Technology, Danvers, MA, USA) for 1 hour at room temperature. Immunoreactive bands were visualized via enhanced chemiluminescence (Amersham Pharmacia Biotech, Little Chalfont, UK) reaction and measured by Quantity One analysis software (Bio-Rad Laboratories Inc, Hercules, CA, USA).

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from livers using Trizol reagent (Thermo Fisher Scientific) following the manufacturer's instructions and cDNA was synthesized using the PrimeScript RT Reagent Kit (TaKaRa, Dalian, China). A qRT-PCR study evaluating the expression of IL-17, IL-23, interferon (IFN)-γ, IL-2, IL-4, and IL-13 was carried out using the QuantiTect SYBR Green RT-PCR Kit on the StepOnePlus™ Real Time PCR System (Thermo Fisher Scientific). Gene expression was standardized to GAPDH expression as an endogenous control, and the relative expression level was calculated by relative quantification ($2^{-\Delta\Delta Ct}$) method. The primers used were

the following: IL-17 – forward: ACCAATCCCAAAGGTCCTC, reverse: GGGGACAGAGTTCATGTGGT; IL-23 – forward: GGGAGATGAAGAGACTACAAA TGATGT, reverse: ATCCTTTGCAAGCAGAAGTACTGACT; IFN-γ – forward: GCATCCAAAAGAGTGTGGAG, reverse: GCAGGCAGGACAACCATTAC; IL-2 – forward: ATGTAC AGGATGCAACTCCTG, reverse: TCAAGTCAGTG TTGAGATGATGCTTTGACAAAA; IL-4 – forward: GCACAAGCAGCTGATCCGAT, reverse: CAGGAA TTCAAGCCCGCC; IL-13 – forward: TTCTACTCAGG TGCTGACCT, reverse: CTGTCTCTGCAAATAATGAT.

Statistical analysis

SPSS 19.0 software (IBM Corporation, Armonk, NY, USA) was utilized for statistical analysis. The data are presented as mean ± standard deviation. Statistical analysis was performed with one-way analysis of variance or Student's *t*-test. $P < 0.05$ was considered statistically significant.

Results

HF alleviates pathologic features in HBV-infected SD rats

The pCDNA3.1 or pCDNA3.1-HBV1.3 plasmids were injected into SD rats to construct animal models of acute hepatitis B infection. In the pCDNA3.1-HBV1.3 group, the concentrations of HBeAg, HBsAg, and HBV DNA in the serum increased from day 1 to day 4 after transfection, and reached the peak of expression at day 4. Then, the levels of HBeAg, HBsAg, and HBV DNA decreased from day 4 to day 10, and were hardly detected at day 10. Compared with the pCDNA3.1-HBV1.3 group, the concentrations of HBeAg, HBsAg, and HBV DNA were obviously depressed by HF at every indicated time in the pCDNA3.1-HBV1.3+HF group (Figure 1A–C). Our results indicated that HF alleviated pathologic features in HBV-infected SD rats.




Figure 1 The expression of HBeAg, HBsAg, and HBV DNA in the serum of transfected rats. Rats were transfected with pCDNA3.1-HBV1.3 or pCDNA3.1, respectively. (A–C) The expression of HBeAg, HBsAg, and HBV DNA at different time points was detected through serological quantitation.

Abbreviations: HBV, hepatitis virus B; HF, halofuginone; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen.

HF protects SD rats from acute hepatitis B by balancing Th17 cells responses

Th17 cells are one of the subtypes of CD4⁺ Th cells which secrete IL-17 cytokine. In our present study, the ratios of Th17 cells in peripheral blood of rats in different groups were analyzed by flow cytometry. Our results indicated that the

ratio of CD4⁺IL-17⁺ cells in rats of the pCDNA3.1-HBV1.3 group was significantly higher compared with the pCDNA3.1 control group. However, HF remarkably reduced the high ratio of CD4⁺IL-17⁺ cells caused by acute HBV infection in the pCDNA3.1-HBV1.3+HF group (***P*<0.001, ##*P*<0.01; Figure 2A and B). The protein level of IL-17 was higher




Figure 2 HF protects SD rats from acute hepatitis B by regulating CD4⁺IL-17⁺ T-cells and expression levels of pro-inflammatory/anti-inflammatory cytokines. Rats were transfected with pCDNA3.1-HBV1.3 or pCDNA3.1, respectively. Rats in the pCDNA3.1-HBV1.3+HF group were transfected with pCDNA3.1-HBV1.3 and supplied with HF. (A) The frequency of CD4⁺IL-17⁺ T-cells in peripheral blood of transfected rats was detected through flow cytometry. (B) The ratio of IL-17 expression from the results of flow cytometry. (C) Relative protein level of IL-17 in livers of transfected rats at different time points was assayed through Western blot. (D) Quantitation of (C). (E–J) Relative mRNA levels of IL-17, IL-23, IFN-γ, IL-2, IL-4, and IL-6 at different time points were assayed through qRT-PCR, respectively. The bars show mean ± standard deviation of 3 independent experiments. **P*<0.05, ***P*<0.01, ****P*<0.001 versus pCDNA3.1 group; #*P*<0.05, ##*P*<0.01, ###*P*<0.001 versus pCDNA3.1-HBV1.3 group.

Abbreviations: HBV, hepatitis virus B; HF, halofuginone; IL, interleukin; IFN, interferon; qRT-PCR, quantitative real-time polymerase chain reaction; SD, Sprague Dawley.

in pCDNA3.1-HBV1.3 group than the pCDNA3.1 group at every indicated time by Western blot analysis. HF also reduced the expression level of IL-17 in the pCDNA3.1-HBV1.3+HF group compared with pCDNA3.1-HBV1.3 group. The expression of IL-17 increased from day 1 to day 4 and decreased from day 4 to day 10 postinjection in both pCDNA3.1-HBV1.3 and pCDNA3.1-HBV1.3+HF groups (* P <0.05, ** P <0.01, *** P <0.001, # P <0.05, ## P <0.01; Figure 2C and D).

Relative mRNA levels of many cytokines (IL-17, IL-23, IFN- γ , IL-2, IL-4, and IL-13) were also compared among these 3 groups mentioned above. In the pCDNA3.1 group, relative mRNA levels of these cytokines were extremely low at different time points without change, indicating that injection of pCDNA3.1 did not influence the concentrations of these cytokines. Acute HBV infection remarkably increased the relative expression of pro-inflammatory cytokines (IL-17, IL-23, IFN- γ , and IL-2) and decreased the relative expression of anti-inflammatory cytokines (IL-4 and IL-13) in SD rats compared with the control group. However, the treatment of HF effectively abrogated the effect of HBV by downregulating the expression of pro-inflammatory cytokines and upregulating the expression of anti-inflammatory cytokines in pCDNA3.1-HBV1.3+HF group compared with the pCDNA3.1-HBV1.3 group (* P <0.05, ** P <0.01, *** P <0.001, # P <0.05, ## P <0.01, ### P <0.001; Figure 2E–J). Our results elucidated that HF suppressed the progression of acute hepatitis B by decreasing the high ratio of Th17 cells and pro-inflammatory cytokines and increasing the expression of anti-inflammatory cytokines in HBV-infected SD rats.

HF-induced AMPK activation is negatively associated with NF- κ B activation with p65 phosphorylation in livers infected with HBV

The AMPK pathway was reported to play an important role in immune response. Therefore, we further investigated whether HF regulated HBV-induced inflammation through the AMPK pathway. Relative expression levels of AMPK and IKBA in the pCDNA3.1-HBV1.3 group were much lower than pCDNA3.1 group and pCDNA3.1-HBV1.3+HF group at every indicated time. In contrast, the expression of p-NF- κ B P65 was largely increased in the pCDNA3.1-HBV1.3 group compared with pCDNA3.1 group, but the elevated level of p-NF- κ B P65 was remarkably decreased by HF in the pCDNA3.1-HBV1.3+HF group compared with pCDNA3.1-HBV1.3 group (* P <0.05, ** P <0.01, *** P <0.001,

P <0.05, ## P <0.01, ### P <0.001; Figure 3A–D). These results suggested that suppression of AMPK by HBV infection was activated by HF and the activation of AMPK was negatively associated with NF- κ B activation with p65 phosphorylation in HBV-infected SD rats.

HF inhibits HBV infection via AMPK-mediated NF- κ B p65 inactivation

In order to further elucidate the potential molecular mechanism of how HF inhibited HBV infection, AMPK inhibitor CC was used in the animal model. After CC treatment, relative expression levels of AMPK and IKBA were decreased while the expression level of p-NF- κ B P65 was increased significantly in pCDNA3.1-HBV1.3+HF+CC group compared with pCDNA3.1-HBV1.3+HF group (* P <0.05, *** P <0.001, # P <0.05, ## P <0.01, \$ P <0.05, \$\$ P <0.01; Figure 4A–D). CC also upregulated the relative expression of IL-17 compared with pCDNA3.1-HBV1.3+HF group (# P <0.05, \$ P <0.05, *** P <0.001; Figure 4E). Results from flow cytometry showed an increased ratio of Th17 cells after CC treatment compared with the pCDNA3.1-HBV1.3+HF group (Figure 4F). These data indicated that HF inhibited HBV infection via AMPK-mediated NF- κ B p65 inactivation.

Discussion

HBV is a common human hepadnavirus which results in various clinical outcomes including acute or chronic hepatitis, liver fibrosis, cirrhosis, or even hepatocellular carcinoma.¹⁹ It has been reported that HBV is a stealth virus which establishes itself efficiently without causing apoptosis or gene expression exchange of hepatocytes.^{20,21} On the contrary, the injury of liver cells is reported to be induced by immune response which may promote hepatic fibrosis during HBV infection.²² Therefore, it is essential to elucidate the related immune reaction after HBV infection.

HF is a plant alkaloid which is extracted from the Chinese herb *D. febrifuga* Lour.⁶ Previous researches have demonstrated the antimalarial, anti-fibrotic, and antitumor functions of HF. Moreover, HF has gained attention for its function as an immune regulator in arthritis.^{15,23} However, the therapeutic efficacy of HF in HBV-infected hepatitis is still elusive; so, further studies are needed.

In our present study, acute HBV-infected animal models were constructed according to previous studies.^{17,24} The concentrations of HBeAg, HBsAg, and HBV DNA were reduced remarkably by HF compared with the control group, indicating that HF suppressed the pathologic progression of HBV infection in SD rats. Moreover, the possible reason for decreasing HBeAg, HBsAg, and HBV DNA




Figure 3 HF-induced AMPK activation is negatively associated with NF- κ B activation with p65 phosphorylation in livers infected with HBV. **(A)** Relative protein levels of AMPK, p-NF- κ B P65, and IKBA in livers of transfected rats at different time points were assayed through Western blot. **(B–D)** Quantitation of the expression of AMPK, p-NF- κ B P65, and IKBA in **(A)**, respectively. The bars show mean \pm standard deviation of 3 independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ compared with pCDNA3.1 group; # $P < 0.05$, ## $P < 0.01$ compared with pCDNA3.1-HBV1.3 group.

Abbreviations: HBV, hepatitis virus B; HF, halofuginone; AMPK, AMP-activated protein kinase.

concentrations from day 4 to day 10 was probably caused by the appearance of the corresponding antibodies heralding the onset of an immune response to the virus in immunocompetent animals.¹⁷ Thus, we further explored the immune response after HBV infection. Previous studies described IL-17 producing CD4⁺ Th17 cells as a subtype of helper CD4⁺ T-cells.^{25,26} Th17 cells which secrete several kinds of cytokines including IL-17 have been reported to play an important role in chronic HBV infection.^{27,28} It has also been reported that Th17 cells are highly enriched in the liver of chronic HBV-infected patients and these were likely to exacerbate liver damage during chronic HBV infection.²⁸ In addition, previous studies revealed that HF decreased the differentiation or the number of Th17 cells in liver fibrosis, autoimmune arthritis, and viral myocarditis animal models.^{15,29,30} In accordance with these previous studies, our data indicated that HF treatment decreased the high expression of Th17 induced by HBV infection, indicating that HF ameliorated the severe Th17-mediated immune response

caused by HBV infection. However, no single cytokine could explain the immune response for there existed many complex cytokine networks in immune reaction. Moreover, our results also showed that HF treatment downregulated the expression of IL-17, IL-23, IFN- γ , and IL-2 and upregulated the expression of IL-4 and IL-13 in acute HBV-infected rats. Cytokines in our study were classified into 2 types: Th1 (pro-inflammatory) cytokines (IL-17, IL-23, IFN- γ , and IL-2) that caused stimulation of virus-specific CD8⁺ cytolytic T lymphocytes, leading to viral clearance and Th2 (anti-inflammatory) cytokines (IL-4 and IL-13) that stimulated activation or differentiation of B cells.^{31,32} However, reports suggest that Th1 lymphocytes contributed not only to virus clearance but also to liver damage and the imbalance of Th1/Th2 played a crucial role in the pathogenesis of HBV infection.^{33,34} Moreover, Sun's research indicated that HF downregulated pro-inflammatory cytokine levels and increased anti-inflammatory cytokine levels in acute viral myocarditis.³⁰ In agreement with Sun's study, our present




Figure 4 HF inhibits HBV infection via AMPK-mediated NF- κ B p65 inactivation. Rats in pCDNA3.1-HBV1.3+HF+CC group were transfected with pCDNA3.1-HBV1.3 and supplied with HF and CC. **(A)** Relative protein levels of AMPK, p-NF- κ B P65, and IKBA in transfected rats were assayed through Western blot. **(B–D)** Quantitation of the expression of AMPK, p-NF- κ B P65, and IKBA in transfected rats was assayed by qRT-PCR. **(E)** Relative mRNA level of IL-17 in transfected rats was assayed by qRT-PCR. **(F)** The frequency of CD4⁺IL-17⁺ T-cells in the peripheral blood of transfected rats was detected through flow cytometry. The bars show mean \pm standard deviation of 3 independent experiments. * P <0.05, *** P <0.001 compared with pCDNA3.1 group; # P <0.05, ## P <0.01 compared with pCDNA3.1-HBV1.3 group; \$ P <0.05, \$\$ P <0.01 compared with pCDNA3.1-HBV1.3+HF group.

Abbreviations: HBV, hepatitis virus B; HF, halofuginone; AMPK, AMP-activated protein kinase; CC, compound C; qRT-PCR, quantitative real-time polymerase chain reaction; IL, interleukin.

data showed that HF reduced the pro-inflammatory cytokines levels and increased anti-inflammatory cytokines in acute HBV-infected SD rats, indicating the anti-inflammatory role of HF in HBV infection.

AMPK has gained much attention as it acts as an attractive target in inflammation control. It was reported that the activation of AMPK inhibited inflammation, serving as a potential target for inflammation disorder diseases

treatment.^{35,36} Moreover, the NF- κ B pathway was reported to be associated with the connections between AMPK and inflammation in some researches. A study by Mo et al revealed that activation of AMPK suppressed NF- κ B signaling and inflammation induced by fatty acid in macrophages.³⁵ Moreover, HF was reported to suppress peripheral blood T-cell functions and pro-inflammatory cytokine production through inactivating NF- κ B.¹⁶ Coincident with previous

reports, the treatment of HF abolished the effect of HBV infection by increasing the expression of AMPK and IKBA and decreasing the expression of p-NF- κ B P65. In contrast, the AMPK inhibitor CC weakened the anti-inflammation effect of HF. Our results indicated that HF played an anti-inflammatory role through AMPK-mediated NF- κ B p65 inactivation in acute HBV-infected hepatitis.

Conclusion

This study explored the function of HF in regulating immune reaction in severe acute HBV-infected SD rats. HF-treated rats exhibited lower concentration of serum antigens and HBV DNA than the control group. HF also reduced the ratio of Th17 cells and pro-inflammatory cytokine levels and increased the anti-inflammatory cytokine levels, demonstrating an anti-inflammatory role via AMPK-mediated NF- κ B p65 inactivation. This study implicated that HF is a potential therapeutic strategy for HBV-infected hepatitis.

Author contributions

All authors contributed equally toward the conception and design of the study, acquisition and interpretation of data, drafting the article, and gave final approval of the version to be published.

Disclosure

The authors report no conflicts of interest in this work.

References

- Liang TJ. Hepatitis B: the virus and disease. *Hepatology*. 2009; 49(5 Suppl):S13–S21.
- Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. *Hepatology*. 2013; 58(1):21–30.
- Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. *Am J Pathol*. 2000;156(4):1117–1132.
- Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. *Annu Rev Pathol*. 2006;1:23–61.
- Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. *J Exp Med*. 1995;181(3):1047–1058.
- Jiang S, Zeng Q, Gettayacamin M, et al. Antimalarial activities and therapeutic properties of febrifugine analogs. *Antimicrob Agents Chemother*. 2005;49(3):1169–1176.
- Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. *Cell Tissue Res*. 2007;328(1):153–166.
- Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. *Biol Blood Marrow Transplant*. 2003;9(7):417–425.
- Huo S, Yu H, Li C, Zhang J, Liu T. Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line. *Int J Clin Exp Pathol*. 2015;8(12):15863–15870.
- Jin ML, Park SY, Kim YH, Park G, Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. *Int J Oncol*. 2014;44(1):309–318.
- Juarez P, Mohammad KS, Yin JJ, et al. Halofuginone inhibits the establishment and progression of melanoma bone metastases. *Cancer Res*. 2012;72(23):6247–6256.
- Roffe S, Hagai Y, Pines M, Halevy O. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. *Exp Cell Res*. 2010;316(6):1061–1069.
- Carlson TJ, Pellerin A, Djuretic IM, et al. Halofuginone-induced amino acid starvation regulates Stat3-dependent Th17 effector function and reduces established autoimmune inflammation. *J Immunol*. 2014;192(5): 2167–2176.
- Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. *J Biol Chem*. 2006;281(22):15090–15098.
- Park MK, Park JS, Park EM, et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. *Arthritis Rheumatol*. 2014;66(5): 1195–1207.
- Leiba M, Cahalon L, Shimoni A, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. *J Leukoc Biol*. 2006;80(2): 399–406.
- Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. *Proc Natl Acad Sci U S A*. 2002;99(21):13825–13830.
- Matthews GV, Ali RJ, Avihingsanon A, et al. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfecting individuals. *PLoS One*. 2013;8(4):e61297.
- McMahon BJ. The natural history of chronic hepatitis B virus infection. *Hepatology*. 2009;49(5 Suppl):S45–S55.
- Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol*. 2005;5(3):215–229.
- Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. *J Virol*. 2005;79(15):9369–9380.
- Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol*. 1995;13:29–60.
- Zeng S, Wang K, Huang M, et al. Halofuginone inhibits TNF-alpha-induced migration and proliferation of fibroblast-like synoviocytes from rheumatoid arthritis patients. *Int Immunopharmacol*. 2017;43:187–194.
- Song XF, Hu TT, Lei Y, et al. Activation of intrahepatic CD4+CXCR5+ T and CD19+ B cells is associated with viral clearance in a mouse model of acute hepatitis B virus infection. *Oncotarget*. 2016;7(32):50952–50962.
- Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. *Annu Rev Immunol*. 2004;22:531–562.
- Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol*. 2007;25:821–852.
- Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. *J Clin Immunol*. 2010;30(1):60–67.
- Call JA, Wilson RJ, Laker RC, Zhang M, Kundu M, Yan Z. Ulk1-mediated autophagy plays an essential role in mitochondrial remodeling and functional regeneration of skeletal muscle. *Am J Physiol Cell Physiol*. 2017;312(6):C724–C732.
- Liang J, Zhang B, Shen RW, et al. The effect of antifibrotic drug halofuginone on Th17 cells in concanavalin A-induced liver fibrosis. *Scand J Immunol*. 2014;79(3):163–172.
- Sun XH, Fu J, Sun DQ. Halofuginone alleviates acute viral myocarditis in suckling BALB/c mice by inhibiting TGF-beta1. *Biochem Biophys Res Commun*. 2016;473(2):558–564.
- Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. *J Leukoc Biol*. 2006;80(6):1197–1213.
- Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. *World J Hepatol*. 2015;7(11):1572–1580.
- Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. *Hepatology*. 1997;25(4):1022–1027.

34. Ye Y, Xie X, Yu J, et al. Involvement of Th17 and Th1 effector responses in patients with hepatitis B. *J Clin Immunol*. 2010;30(4):546–555.
35. Mo C, Wang L, Zhang J, et al. The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. *Antioxid Redox Signal*. 2014;20(4):574–588.
36. Zong Y, Sun L, Liu B, et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. *PLoS One*. 2012;7(8):e44107.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>